BAC has entered into a collaboration with GE Healthcare to develop and market affinity chromatography media for the purification of therapeutic recombinant FVIII
BAC will provide its CaptureSelect affinity ligands, renowned for their high stability and specificity, to enable efficient process-scale purification of FVIII for the prevention and treatment of bleeding in patients with Haemophilia A.
CaptureSelect ligands exploit the nature of Camelid single chain antibody fragments and offer enhanced stability and broad antigen-specific binding compared to traditional affinity ligands.
These affinity ligands are manufactured using a high-yielding proprietary yeast-based expression system, which is completely animal-free.
BAC says it can rapidly discover and develop CaptureSelect ligands for chromatographic separations that can be customised for use in the manufacture of a range of biopharmaceuticals, including recombinant proteins, antibodies, antibody fragments and viruses.
"We are extremely pleased that GE Healthcare wishes to further develop and distribute our recombinant FVIII purification ligand products," commented Laurens Sierkstra, CEO of BAC.
"This agreement endorses our technology and extends its accessibility to GE's customers worldwide."
